The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study
Background Generally, an induction agent is chosen based on the conditions of the deceased donor and the recipient. Antithymocyte globulin (ATG) is preferred in relatively high-risk conditions. No clear evidence indicates which induction agent is safer or more efficient for deceased donor kidney tra...
Main Authors: | Su Yeon Hong, Young Soo Kim, Kyubok Jin, Seungyeup Han, Chul Woo Yang, Byung Ha Chung, Woo Yeong Park |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Nephrology
2023-01-01
|
Series: | Kidney Research and Clinical Practice |
Subjects: | |
Online Access: | http://krcp-ksn.org/upload/pdf/j-krcp-21-159.pdf |
Similar Items
-
Impact of delayed graft function on clinical outcomes in highly sensitized patients after deceased-donor kidney transplantation
by: Seong Gyu Kim, et al.
Published: (2021-09-01) -
Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review
by: Bruno Mendes, et al.
Published: (2022-08-01) -
Clinical significance of de novo donor-specific antibody in kidney transplant recipients with chronic antibody-mediated rejection
by: Woo Yeong Park, et al.
Published: (2021-03-01) -
Comparison of clinical outcomes of deceased donor kidney transplantations, with a focus on three induction therapies
by: Eun Sung Jeong, et al.
Published: (2019-12-01) -
Outcomes and Complications of Donor and Recipient of Renal Transplantation: An Experience from Tertiary Care Center – A Retrospective Observational Study
by: Sahil Punia, et al.
Published: (2024-06-01)